JCR To Be First To Produce Local Biotech Generic In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's JCR Pharmaceuticals plans to make its entry into the mass-produced biotech generic sector in Japan with an erythropoietin protein-based treatment for anemia due to reduced kidney function. JCR said it expects to get government clearance for its generic at the beginning of next year and then produce it in a special factory it plans to construct by next summer. The JCR drug would be only the second bioengineered generic to be approved for sale in the country, the first being a human growth hormone that Sandoz imports from Australia. JCR plans to co-market the drug with Kissei Pharmaceutical. (Click here for more - a subscription may be required